Zonisamide (ZNS) is effective and well tolerated when used as adjunctive therapy in the treatment of partial epilepsies. The aim of our study is to evaluate the effect of ZNS on background activity organisation and preexisting abnormalities in patients with epilepsy. We studied 15 patients (mean age 39.4 ± 16.8 aa) treated with ZNS in add-on (daily dose: 350 ± 51 mg) for 12-54 weeks (average: 31 ± 17 weeks). Inspective analysis showed that most of EEG recordings were unchanged. Quantitative analysis showed a slight increment of delta-theta activity compared to the baseline, Our preliminary study suggests that, in general, ZNS has good neurophysiologic tolerability in epileptic patients.
|Translated title of the contribution||Effects of zonisamide on EEG: A quantitative and inspective study in patients with epilepsy|
|Number of pages||2|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - May 2008|
ASJC Scopus subject areas
- Clinical Neurology